Hypertension and nephrology

[Changing dietary guidelines in obesity. MOMOT recommendation]


DECEMBER 20, 2014

Hypertension and nephrology - 2014;18(05-06)

[In the 70s and 80s due to the heart attack „epidemic” the low fat diet was encouraged based on the cholesterol theory, with moderate success. At the same time, the consumption of carbohydrates increased with the frequency of obesity rising from 1971 to 30% in the USA. Foods with high glicemic index and rich in carbohydrates result in a fast increase in glucose level, insuline actions also leading to glucose – fatty acid transformation and weight gain. Over the last decades several comparative trials have proven that with the low carb diet one can lose about 3- more than with the low fat diet in half a year. The excessive low carbohydrate Atkins diet over 1 year (), was superior even to ZONE (), LEARN (), ORNISH () diet, in another trial, over two years also the „low fat” diet. International Association for the Study of Obesity (IASO) recommends an increased protein intake (15 → 25%) along with carbohydrate with low glicemic index (GI). According to the summarized guidelines of the Hungarian Society of Obesitology and Excercise Therapy (MOMOT) low calorie (1200-1500 kcal / day), low-carb (<45%) – low-GI, high-protein (≥ 25%), low-fat (38→30%) diet is recommended, by witch a weight loss of 10 kg/half year can be expected. After half a year patient compliance deteriorates and they can hardly keep even the low-carb diet, whose significant advantage diminishes by this. We hope that patient compliance can be helped with two new appetite decreasing drugs, namely lorcaserin and a combination of phentermin and topiramat. Future dietary recommendations may be influenced by the new guideline issued in November 2013 by AHA/ACC, and the Obesity Society the final approval of which by NHLBI can be expected by June 2014.]


  1. Szent Imre Egyetemi Oktatókórház, Budapest



Further articles in this publication

Hypertension and nephrology

[The Comprehensive Hungarian Screening Program for Health Protection 2010-2020]

KISS István, DANKOVICS Gergely

Hypertension and nephrology

[The Juxtaglomerular Apparatus – Structure and Functioning of the Kidney’s “Brain”: Message and Conclusions of an Article Series Resulting from Decades of Research]


Hypertension and nephrology

[Epidemiology of hypertension in Hungary]


[The most important aspects of Hungarian hypertension epidemiology are demonstrated. The prevalence of hypertension is continuously increasing and in 2011 from the nearly 10 million population exceeded 3 million. Its occurrence rises in parallel with the increase in of systolic blood pressure and the progression of age, and exceeds 60% in those aged over 65 years. The average blood pressure is increasing in children and adolescents, and isolated systolic hypertension is often observed in those over 65-70 years. The situation is closely related to overweight in the young, while in elderly the atherosclerotic process results in low diastolic blood pressure. The prevalence is significantly different in some regions with the highest incidence in South-Transdanubia and North- Hungary. Overall, there is a higher incidence in women. Among known hypertensive patients, the ratio of men is greater till 40-45 years; thereafter, there will be an equilibration and in elderly women the incidence will be higher. It is interesting, that the morbidity and mortality have significantly increased in hypertension and diabetes since 2004, while the incidence of myocardial infarction and stroke has significantly decreased. As concerns organ damage, an increase in occurrence of left ventricular hypertrophy and microalbuminuria has been observed. Metabolic syndrome, diabetes mellitus and ischemic heart disease were the most frequent comorbidities.]

Hypertension and nephrology

[Guide for using methods of cardiovascular risk estimation]


[Author analyzes the most frequently used, reliable cardiovascular risk estimation methods. Only those methods are useful that meet to the american and european prevention guidelines and were edited by processing of the great databases. The best known risk estimation methods are continuously is expanding by growing body of knowledge and by another iseful risk factors, because the only way in order to successfully prevent the cardiovascular diseases. Two types of method-groups are known: 1. Traditional narrowed form for the general practisers and for the large section of population, 2. Methods with a broader analysis and more risk factors for the specialists and scientists. In Europe PROCAM and Heart Score and their variations are most useful for the practical medical work, but it is possible to use the american ASCVD and Reynolds risk estimation methods as well using the help of the national correction factors. The methods with wider analysis and much more risk factors as the Mayo Clinic mode, Qrisk2 and IHMRS are suitable in assisting of the epidemiologic studies or scientific work.]

Hypertension and nephrology

[Chronic Kidney Disease in Disadvantaged Populations]


All articles in the issue

Related contents

Clinical Neuroscience

Positive airway pressure normalizes glucose metabolism in obstructive sleep apnea independent of diabetes and obesity

KABELOĞLU Vasfiye, SENEL Benbir Gulçin, KARADENIZ Derya

The relationship among obstructive sleep apnea syndrome (OSAS), type 2 diabetes mellitus (DM2) and obesity is very complex and multi-directional. Obesity and increased visceral fat are important perpetuating factors for DM2 in patients with OSAS. On the other hand, OSAS itself leads to obesity by causing both leptin and insulin resistance as a consequence of activation of the sympathetic nervous system. Risk for developing DM2 further increases in patients with OSAS and obesity. Data regarding effects of positive airway pressure (PAP) therapy, gold standard treatment for OSAS, on glycemic control were inconsistent due to variability in duration of and adherence to PAP therapy. In our cohort study we investigated effects of PAP treatment on glucose metabolism in normal-weighted non-diabetic OSAS patients, in obese non-diabetic OSAS patients, and in OSAS patients with DM2. We prospectively analyzed 67 patients diagnosed with OSAS and documented to be effectively treated with PAP therapy for three months. Apnea-hypopnea index was highest in the diabetic group, being significantly higher than in the normal-weighted group (p=0.021). Mean HOMA values were significantly higher in obese (p=0.002) and diabetic group (p=0.001) than normal-weighted group; the differences were still significant after PAP therapy. HbA1c levels were significantly higher in diabetic group compared to those in normal-weighted (p=0.012) and obese (p=0.001) groups. After PAP treatment, decrease in HbA1c levels were significant in normal-weighted (p=0.008), obese (p=0.034), and diabetic (p=0.011) groups. There was no correlation with the change in HbA1c levels and age (p=0.212), BMI (p=0.322), AHI (p=0.098) or oxygen levels (p=0.122). Our study showed that treatment of OSAS by PAP therapy offers beneficial effect on glucose metabolism, not only in diabetic patients, but also in obese and normal-weighted OSAS patients. Although data regarding overall effects of PAP therapy on glycemic control present contradictory results in the literature, it should be emphasized that duration and adherence to PAP therapy were main determinants for beneficial outcome of treatment.

Lege Artis Medicinae

[The possibilities of pharmacological treatment of obesity]

PADOS Gyula, SIMONYI Gábor, BEDROS J. Róbert

[There have been attempts to treat obesity with medicines for nearly 100 years, since the discovery of ephedrine. For decades amphetamine derivates and agents stimulating or inhibiting the release of noradrenaline and dopamine have been applied. However, most of theses drugs had to be gradually withdrawn, due to their adverse effects on the cardiovascular and central nervous system or their sympaticotonic effect. Dexfenfluramine (Isolipan), which was introduced in the 90s, did not have such side effects, but it turned out to potentially cause valvular heart disease. Finally, sibutramin (Reductil) was introduced, which again had to be withdrawn in 2010 due to its hypertensive and cardiovascular side effects. After all, we were left without any appetite-suppressant drugs. Orlistat therapy, (Xenical 120 mg, alli 60 mg - OTC), which inhibits the absorption of fat, can eliminate only 30% of the consumed food’s fat content, at the price of gastrointestinal side effects. The latest result of research carried out wordwide is that in 2012 the FDA approved commercial distribution of the selective 5HT2/c serotonin agonist lorcaserin (Belviq), which enhances satiety, in the USA. Unfortunately, in 2013 the EMEA temporarily postponed the lauch of this drug, until certain adverse effects are excluded. For diabetic patients, the GLP-1 agonist exenatid and the GLP-analog liraglutid, which can also reduce body weight, are available in the form of injections.]

Clinical Oncology

[Obesity and cancer]


[The role of obesity in the development of cancer is well-known from ages. However, these days we witness the explosion-like increase of obesity, globally, but mainly in the economically advanced population, and, which is even more alarming, among youngsters. The prognosis of the obesity-related cancer is rather poor, therefore, the prevention, including the screening, have outstanding importance. Unfortunately, the participation of the obes persons, especially obes women, in these programs is very low. The diagnostics and therapies should consider the special features of obesity, which are related to the magnitude, distribution, composition of fatty tissue connected to the changes in pharmacokinetics. Moreover, the problems might be complicated with obesity-associated non-tumorous severe diseases (e.g. cardiovascular, diabetes type 2).This review covers different aspects of obesity-cancer relationships, with an emphasis on everyday oncology.]

Lege Artis Medicinae



[The prevalence of type 2 diabetes mellitus has recently dramatically increased worldwide. While many factors contribute to the startling data, including changes in the diagnostic criteria of glucose intolerance, increase of life expectancy, manifestation of diabetes at younger ages, and increased detection of unrecognized diabetes due to more efficient screening, the genuine, steep rise in the incidence of diabetes is explained by the increasing prevalence of obesity. Among the late complications of both diabetes and obesity, cardiovascular diseases are particularly important. Insulin resistance due to visceral obesity plays a central role in the pathomechanism of type 2 diabetes. In the prevention of both type 2 diabetes and obesity, non-pharmacological intervention such as life style changes should be considered first. Supplementary pharmacological treatment should target all cardiovascular risk factors.]

Hypertension and nephrology

[Deeper analysis of nebivolol effects]


[Author presents the formation of nitric oxide as a largest vasodilator of human endothelium as well as the endothelial dysfunction a result of formation at adrenergic stimulus. He demonstrates in detail the benefits of selective β-1 blocker and β-3 adrenergic agonist nebivolol in the vascular system. This drug has also receptor independent effects. Complex effects of nebivolol causes vasodilation, inhibits oxidative stress and it is capable to neutralize the effects of free oxygen radicals and as a result the endothelial function will be better. Its clinical effects and the less wellknown beneficial properties are listed. The use of drug is discussed especially in hypertensives with smoking, COPD or PAD. The β-3 agonist effect provides positive reactions not only in the adipocytes and the myocardial tissue. but in the skeletal muscle as well: Increase in energy expenditure - as a compensatory mechanism - is increased in obesity and the glucose uptake + storage on skeletal muscle cells are increased in hyperglycemia. The insulin sensitivity will be better, leptin level is decreased, adiponectin level is increased by nebivolol. It is assumed this drug has antidiabetic and anti-obesity effects.]